How many times have you started to have a conversation with someone about Hepatitis C only to have it blow up in your face? Have you ever heard someone say something about Hep C that didn't seem quite right to you? You were probably right something was amiss. A discussion about Hepatitis C can...
As per Wikipedia, the definition of a stigma is as follows: "Stigma is a word that originally means a "sign", "point", or "branding mark"." Wikipedia goes on to call stigma "A badge of shame, a physical mark of infamy or disgrace." Damn that w...
Recently, the CDC (Center for Disease Control) issued a statement that all Baby Boomers should be tested for Hepatitis C. The question often comes up as to why this particular segment of people is so vulnerable. What does being born between 1945 and 1965 have to do with Hepatitis C? What was di...
Buyer Beware! There are several snake oil salesmen out there who are claiming to have cured their own Hepatitis C with herbs, supplements and parking lot gravel. Okay, maybe not the parking lot gravel but it might as well be. What you need to remember is that there are two different types of...
Most every adult woman (and an occasional man) has enjoyed a manicure and a pedicure at a nail salon or spa. That 30 minute pedicure can be so relaxing but are you aware of the danger lurking in that nail salon? Although few individuals recognize the medical risks associated with this common pr...
Introduction.
Despite the strong evidence for the effectiveness of anti-retroviral (ARV) drugs for improving the health of HIV-infected women and for the prevention of mother-to-child transmission (PMTCT) [1], [2], HIV-related morbidity and mortality among childbearing women and vertical transmission of HIV from mother to child continue to be major health problems in sub-Saharan Africa [3], [4]. In order to improve health outcomes, women need to successfully navigate a cascade of services including antenatal care (ANC) clinic attendance, acceptance of HIV testing, receipt of results, enrollment in HIV care, acceptance of ARV prophylaxis or treatment, adherence with maternal antiretroviral (ARV) prophylaxis or treatment, adherence to infant ARV prophylactic doses, and early infant HIV testing [5].
Unfortunately, a significant proportion of women and their infants drop out at each step along this cascade thus decreasing the effectiveness of PMTCT programs [6]–[9]. The 2009 Expert Consultation on Implementation Science Research sponsored by the NIH Office of AIDS Research identified as a top priority research on how to promote women’s linkage to and retention in care at each step of this PMTCT cascade [10].
One promising approach for improving linkages to and retention in services for women and infants is to fully integrate HIV care into ANC clinics [11]. Although definitions of “integration” vary, experiences in sub-Saharan Africa suggest that integrating ANC and HIV services may result in a variety of benefits for HIV-positive women and their families; including better uptake of services, more women receiving counselling, reduction of the time to treatment initiation, improved quality of care, and reduction of stigma [12]–[17]. Lack of integration of PMTCT into routine maternal and child health services has been identified as one of the major contributors to drop-off of women and infants at various steps in the PMTCT cascade [18]. On the other hand, the potential downsides of integration in low-resource settings include: increased provider workload in an already overburdened system, increased training needs, lack of space and equipment, lack of staff motivation to provide more services, and even “organizational culture clash” [19]–[21]. From the perspective of clients, it is possible that integration of HIV services into ANC clinics could have negative effects–such as increased wait times–for the majority of clients who are HIV-negative [22].
Since 92% of women in Kenya have at least one antenatal care visit during pregnancy, ANC clinics have become prime locations for expansion of HIV testing and PMTCT services in this country [23]. Due to these efforts, rates of antenatal HIV testing have been increasing over time in Kenya – approximately 73% of pregnant women were tested during 2008–2009 [23]; however, only an estimated 72% of pregnant women who tested HIV-positive received antiretroviral medications for PMTCT in 2009 [24]. Antenatal care has been modified to include PMTCT services, but generally has not included comprehensive HIV care and treatment for pregnant women. Comprehensive HIV care and treatment encompasses the clinical and social components necessary for the highest quality of care, including opportunistic infection prophylaxis, tuberculosis (TB) diagnosis and treatment, WHO clinical staging for HIV, highly active antiretroviral therapy (HAART), CD4 count monitoring, relevant laboratory tests (such as complete blood counts, creatinine, liver enzymes, etc.), adherence counseling, peer education, and access to support groups. In most ANC clinics in Kenya, HIV-positive pregnant women are normally referred to a separate HIV clinic for care and treatment (either located elsewhere on the grounds of the health facility or at another health facility), which may operate at different times and days than the ANC clinic.
As elsewhere, the Kenyan national guidelines for PMTCT–including recommendations for infant feeding, CD4 count monitoring, and HAART initiation–have been evolving over time. In August 2010 the Kenyan PMTCT guidelines were updated [25]. These guidelines recommended earlier initiation of HAART for a larger group of HIV-positive pregnant women (WHO clinical stage III or IV regardless of CD4 count OR WHO clinical stage I or II with CD4 count <350/mm3, compared with previous recommendations of WHO clinical stage of III or IV OR CD4 count <200/mm3) to benefit both the health of the mother and prevent HIV transmission to her child during pregnancy and breastfeeding. The ARV prophylaxis regimen guidelines were also changed in 2010, to start at 14 weeks or at first contact thereafter, compared with previous guidelines that recommended initiating prophylaxis at 28 weeks. The new PMTCT guidelines also include provision of ARV prophylaxis (zidovudine and lamivudine) to the mother for 7 days after the delivery and daily infant prophylaxis with nevirapine (NVP) monotherapy until one week after breastfeeding cessation if mother is not on HAART or up to 6 weeks of age if mother is on HAART.
Abstract
Background
Despite strong evidence for the effectiveness of anti-retroviral therapy for improving the health of women living with HIV and for the prevention of mother-to-child transmission (PMTCT), HIV persists as a major maternal and child health problem in sub-Saharan Africa. In most settings antenatal care (ANC) services and HIV treatment services are offered in separate clinics. Integrating these services may result in better uptake of services, reduction of the time to treatment initiation, better adherence, and reduction of stigma.
Methodology/Principal Findings
A prospective cluster randomized controlled trial design was used to evaluate the effects of integrating HIV treatment into ANC clinics at government health facilities in rural Kenya. Twelve facilities were randomized to provide either fully integrated services (ANC, PMTCT, and HIV treatment services all delivered in the ANC clinic) or non-integrated services (ANC clinics provided ANC and basic PMTCT services and referred clients to a separate HIV clinic for HIV treatment). During June 2009– March 2011, 1,172 HIV-positive pregnant women were enrolled in the study. The main study outcomes are rates of maternal enrollment in HIV care and treatment, infant HIV testing uptake, and HIV-free infant survival. Baseline results revealed that the intervention and control cohorts were similar with respect to socio-demographics, male partner HIV testing, sero-discordance of the couple, obstetric history, baseline CD4 count, and WHO Stage. Challenges faced while conducting this trial at low-resource rural health facilities included frequent staff turnover, stock-outs of essential supplies, transportation challenges, and changes in national guidelines.
Conclusions/Significance
This is the first randomized trial of ANC and HIV service integration to be conducted in rural Africa. It is expected that the study will provide critical evidence regarding the implementation and effectiveness of this service delivery strategy, with important implications for programs striving to eliminate vertical transmission of HIV and improve maternal health.
Please sign the ATC Salvage Therapy Petition Join us in asking Congressman Alcee Hastings and Congresswomen Maxine Waters to send a ‘Dear Colleague’ letter to Anthony Fauci, Director of NIAID, asking for the federal facilitation of apricitabine (ATC). ATC is a phase III nucleoside reverse transcriptase inhibitor (NRTI) that has been shown to be safe and effective in treating people with HIV. It works against viruses that are resistant to several other nukes and could ...
Researchers from Johns Hopkins Children’s Center, the University of Mississippi Medical Center and the University of Massachusetts Medical School announced today at CROI2013 the discovery of the first infant functionally cured of HIV. The baby, a female now two and a half years old, received 3 HIV medications when brought to the hospital at 30 hours old. Viral load tests were performed during the first few weeks that showed a rapidly decreasing viral load which reached ...
At the 19th International AIDS Conference (AIDS 2012) in Washington D.C., the CDC reported that only 1 out of 4 HIV patients in the U.S. have HIV under control, which is defined as complete viral suppression. Warning bells should be ringing in the scientific and HIV advocacy communities. While much progress has been made in the last three decades in the treatment of HIV, tens of thousands of people living with HIV (PLWH) are currently struggling to construct viable treat...
Paige Rawl is 17 and HIV positive, but while her life has been shaped by HIV it isn't ruled by it. When Paige Rawl starts her senior year at Indianapolis’s Herron High School next month, she'll be cheer captain and a member of the student government and prom committee. This summer, the 17-year-old held down a part-time job at Hollister, hawking the popular Southern California-inspired clothing brand. The all-American girl — who happens to be HIV positive. Paige was in...
The HIV community has been abuzz with the August FDA approval of what had been termed “the Quad”, the second one-pill-once-a-day combination antiretroviral drug. Marketed by Gilead under the name Stribild, the drug contains two NRTIs (tenofovir and emtricitabine), an integrase inhibitor (elvitegravir) and an integrase booster (cobicistat) and is approved for use in treatment naïve patients with either drug resistant or wild type virus. In comparison to Atripla, the first...

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for SUSTIVA® (efavirenz), including dosing recommendations for...

California and other states would be pressured to amend or repeal criminal laws that single out HIV-positive people under a bipartisan bill co-authored and introduced this week by Rep. Barbara...
Mission Statement
At HIV Haven we wish to provide our readers with vital cutting edge information to help expand HIV knowledge and promote activism, particularly that which works towards an end to the HIV pandemic. It is our desire to bring to you the scientific, medical and social advances that given the appropriate attention and support, could change the course of the HIV pandemic, lessen the devastating effects of HIV and AIDS, better the quality and quantity of life for people living with HIV and even yield an eventual end to the HIV pandemic. We also provide the basics of HIV transmission and treatment.
We will focus on issues such as innovative drug development, strategic activist campaigns, HIV relationships and novel HIV and HIV cure research. We also will bring you advances in Hepatitis C (HCV), a common HIV co-infection. Whether you are living with HIV/AIDS, HIV and HCV, love someone who is, are an activist, advocate, researcher, physician or just an interested party, we hope here at HIV Haven we can help you find what you are looking for.